TACE治疗原发性肝癌患者的效果和安全性  

Efficacy and Safety of TACE in the Treatment of Primary Liver Cancer

作　　者：李鹏飞[1] 鲍乐[1] 王友彬[1] 陈龙 郭爱军[1] LI Pengfei;BAO Le;WANG Youbin;CHEN Long;GUO Aijun(Department of Interventional,Xuzhou Cancer Hospital,Xuzhou Jiangsu 221000,China)

机构地区：[1]徐州市肿瘤医院介入科

出　　处：《中国继续医学教育》2019年第35期127-130,共4页China Continuing Medical Education

摘　　要：目的探究肝动脉化疗栓塞(TACE)对原发性肝癌患者甲胎蛋白(AFP)及预后情况的影响。方法选取本院2014年4月-2017年4月期间经血清和影像学检查证实的116例原发性肝癌患者作为研究对象,随机分对照组和研究组,各58例。对照组给予索拉非尼靶向治疗,研究组给予肝动脉化疗栓塞术治疗。对比分析两组患者治疗效果、AFP含量、肝功能情况、免疫功能情况和存活率。结果研究组治疗有效率明显高于对照组(P <0.05);两组患者AFP和AFP-L3含量均显著降低,且研究组降低程度更高(P <0.05);治疗前相比;半年存活率和一年存活率差异无统计学意义(P> 0.05),研究组患者两年存活率显著高于对照组(P <0.05)。结论 TACE在治疗原发性肝癌具有显著疗效,不仅能够降低机体内AFP含量,而且提高患者生存质量。Objective To explore the effect of TACE on AFP and prognosis in patients with primary liver cancer.Methods A total of 116 patients with primary liver cancer confirmed by serum and imaging examination from April 2014 to April 2017 in our hospital were selected as subjects.They were randomly divided into study group and control group,each with 58 cases.The control group patients were treated with sorafenib targeted therapy.The study group patients were treated with transcatheter arterial chemoembolization.Therapeutic effect,AFP content,liver function,immune function and survival rate between the two groups were compared.Results The treatment effect of the study group was significantly better than the control group(P < 0.05).AFP and AFP-L3 levels were significantly lower in both groups.The AFP and AFP-L3 levels in the study group were lower than those in the control group(P < 0.05).There was no significant difference between the half-year survival rate and the one-year survival rate(P > 0.05).The two-year survival rate of the study group was significantly higher than that of the control group(P < 0.05).Conclusion TACE has significant efficacy in the treatment of primary liver cancer.Not only can reduce the body’s AFP content,but also improve the quality of life of patients.

关 键 词：肝动脉化疗栓塞 索拉非尼靶向治疗 原发性肝癌 甲胎蛋白 预后 肝功能衰竭 

分 类 号：R735.7[医药卫生—肿瘤]